To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Lab901 Extends ScreenTape User Base for Automated SDS-PAGE; Plans US Launch
Read time: Less than a minute
Lab901 announced an extension of the user base for its protein ScreenTape platform for automated, rapid SDS-PAGE.
The company has completed new shipments of ScreenTape systems to ESBATech, Crucell, Symphogen, Bayer Healthcare and multiple systems to Novartis Basel.
‘We are delighted that so many premier bio-pharmaceutical companies are adding ScreenTape to their protein and antibody production workflows,’ commented Richard Rowling from Lab901. ‘The time savings and efficiency gains of completing SDS-PAGE and full analysis within minutes instead of hours, seems to be particularly important to our customers who are trying to achieve more with fewer resources,’ he added.
Lab901 recently expanded the application base for protein ScreenTape to ‘At-line’ monitoring of monoclonal antibody production and presented at the PepTalk meeting in San Diego.
‘We’ve experienced a strong demand for our protein ScreenTape system in Europe and are now generating a lot of interest in the US,’ said Joel Fearnley (CEO, Lab901). ‘The time is right to start selling ScreenTape to our biggest potential market in North America.’
The protein ScreenTape systems offer fully automated SDS-PAGE and analysis in under 1 minute per sample. Users are provided with a gel image, electropherogram and information such as molecular weight, percentage purity and quantity in a fraction of the time needed when using traditional pre-cast gel methods. Unused lanes on ScreenTape can be used for subsequent experiments making the system more cost-effective than pre-cast gels or micro-fluidic chips, the company said.
The company has completed new shipments of ScreenTape systems to ESBATech, Crucell, Symphogen, Bayer Healthcare and multiple systems to Novartis Basel.
‘We are delighted that so many premier bio-pharmaceutical companies are adding ScreenTape to their protein and antibody production workflows,’ commented Richard Rowling from Lab901. ‘The time savings and efficiency gains of completing SDS-PAGE and full analysis within minutes instead of hours, seems to be particularly important to our customers who are trying to achieve more with fewer resources,’ he added.
Lab901 recently expanded the application base for protein ScreenTape to ‘At-line’ monitoring of monoclonal antibody production and presented at the PepTalk meeting in San Diego.
‘We’ve experienced a strong demand for our protein ScreenTape system in Europe and are now generating a lot of interest in the US,’ said Joel Fearnley (CEO, Lab901). ‘The time is right to start selling ScreenTape to our biggest potential market in North America.’
The protein ScreenTape systems offer fully automated SDS-PAGE and analysis in under 1 minute per sample. Users are provided with a gel image, electropherogram and information such as molecular weight, percentage purity and quantity in a fraction of the time needed when using traditional pre-cast gel methods. Unused lanes on ScreenTape can be used for subsequent experiments making the system more cost-effective than pre-cast gels or micro-fluidic chips, the company said.
